Akebia Therapeutics
(AKBA)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Sales | 160,180 | 194,623 | 292,484 | 211,650 | 294,644 |
| Cost of Goods | 63,177 | 74,149 | 85,568 | 150,671 | 182,052 |
| Gross Profit | 97,003 | 120,474 | 206,916 | 60,979 | 112,592 |
| Operating Expenses | 147,652 | 166,879 | 288,263 | 326,152 | 490,470 |
| Operating Income | -50,472 | -46,256 | -80,779 | -264,502 | -377,826 |
| Interest Expense | 18,185 | 6,032 | 15,687 | 19,936 | 8,871 |
| Other Income | -753 | 363 | 2,240 | 2,414 | 1,856 |
| Pre-tax Income | -69,410 | -51,925 | -94,226 | -282,024 | -384,841 |
| Net Income Continuous | -69,410 | -51,925 | -94,226 | -282,024 | -384,841 |
| Net Income | $-69,410 | $-51,925 | $-94,226 | $-282,024 | $-384,841 |
| EPS Basic Total Ops | -0.33 | -0.28 | -0.52 | -1.70 | -2.78 |
| EPS Basic Continuous Ops | -0.33 | -0.28 | -0.52 | -1.70 | -2.78 |
| EPS Diluted Total Ops | -0.33 | -0.28 | -0.52 | -1.70 | -2.78 |
| EPS Diluted Continuous Ops | -0.33 | -0.28 | -0.52 | -1.70 | -2.78 |
| EPS Diluted Before Non-Recurring Items | -0.33 | -0.28 | -0.43 | -1.70 | -1.93 |
| EBITDA(a) | $-8,770 | $-4,410 | $-43,082 | $-226,547 | $-228,756 |